EWC Code
Spent catalysts containing gold, silver, rhenium, rhodium, palladium, iridium or platinum
EUR-Lex Commission Decision 2000/532/EC — Official Journal L 226, 06/09/2000Annual Volume (EU)
~500 kt–1 Mt/year pharmaceutical manufacturing waste
Valorisation Range
Solvent recovery €150–600/t; precious metal catalyst recovery €1000–5000/t
Primary Route
Solvent recovery and reuse
Need verified buyer contacts with location-specific pricing?
Get contacts for EWC 16 08 01EWC 16 08 01 is a specific sub-code under EWC 07 05 — Wastes from manufacture, formulation, supply and use of pharmaceuticals. The classification guidance below applies to this waste stream.
EWC 07 05 covers wastes from active pharmaceutical ingredient (API) synthesis, drug formulation, and associated laboratory and clinical waste. Key hazardous sub-codes: 07 05 01* (aqueous washing liquids and mother liquors), 07 05 03* (halogenated solvents), 07 05 04* (other solvents), 07 05 07* (halogenated still bottoms), 07 05 08* (other still bottoms). Non-hazardous pharmaceutical solid waste is 07 05 14.
Multi-step organic synthesis for API production generates large solvent volumes — the pharmaceutical industry is one of the highest users of solvents per kg of product (E-factor up to 100 in complex synthesis). Key solvents: dichloromethane, THF, acetonitrile, methanol, IPA, toluene. Solvent recovery by distillation is standard practice; recovered solvents reused on-site or sold. Fermentation-derived APIs generate biological waste streams — spent fermentation broth, mycelium cake.
Cytotoxic and antibiotic manufacturing wastes require segregated incineration — cytotoxics (anticancer drugs) to prevent environmental mutagenic/carcinogenic contamination; antibiotics to prevent antibiotic resistance dissemination. Homogeneous and heterogeneous precious metal catalysts (Pd, Pt, Rh) are recovered by specialist refiners with high economic return.
Typical Generators
Established valorisation pathways for EWC 16 08 01, ranked by economic value and market depth.
Mother liquors and solvent wash streams distilled to recover DMF, DCM, acetonitrile, THF and other solvents. Recovered solvent tested by GC analysis against acceptance specification before return to formulation or sale. Distillation still bottoms (07 05 07*, 07 05 08*) separately managed.
Spent Pd/C, Pd(OH)₂, Pt/C and Rh catalysts returned to precious metal refiners (Johnson Matthey, Umicore) under consignment/weighback agreements. Typical Pd recovery 97–99%. Return credit substantially reduces net waste management cost.
Cytotoxic drug waste (mother liquors, still bottoms, out-of-spec API) incinerated at ≥1100°C at permitted hazardous waste facility. Antibiotic waste incinerated to prevent AMR dissemination. Full combustion verification required; no co-disposal with general pharmaceutical waste.
These are the established routes for EWC 16 08 01. Which one your stream qualifies for depends on its composition, volume and region.
Get the ranked options for your streamPrimary & secondary off-takers
API manufacturers generate the majority of 07 05 waste; in-house solvent recovery and catalyst management
Specialist refineries recover palladium, platinum and rhodium from spent pharmaceutical catalysts
Specialist solvent recovery contractors serve pharmaceutical industry under GMP-compliant logistics
Cytotoxic and antibiotic waste incineration operators
Common materials that take EWC 16 08 01 depending on where the waste arises.
Dedicated waste-stream pages covering EWC 16 08 01 — pricing, buyer industries and valorisation routes.
Sectors that valorise EWC 16 08 01 as an input material or secondary raw material.
Leave your work email. Our industrial desk sends verified company contacts with location-specific pricing and contract minimums for spent catalysts containing gold, silver, rhenium, rhodium, palladium, iridium or platinum — not generic benchmarks.
Reviewed by our industrial desk within 1 business day.